Related Experiment Videos
Neuromuscular blocking agents in paediatric anaesthesia
1Department of Anesthesia, University of California, San Francisco 94143-0648, USA.
Insights
Newer neuromuscular blocking agents offer advantages over succinylcholine in pediatric anesthesia. Rocuronium and rapacuronium provide rapid onset and offset, similar to succinylcholine but with fewer adverse effects.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- Neuromuscular blocking agents are essential in pediatric anesthesia for intubation and surgery.
- Pediatric patients exhibit unique pharmacokinetic and pharmacodynamic profiles compared to adults.
Purpose of the Study:
- To compare the efficacy and safety of newer non-depolarizing neuromuscular blocking agents with succinylcholine in pediatric anesthesia.
- To evaluate the onset and offset characteristics of mivacurium, rocuronium, and rapacuronium in pediatric patients.
Main Methods:
- Comparative analysis of pharmacokinetic and pharmacodynamic data in pediatric patients.
- Review of clinical studies and regulatory information regarding neuromuscular blocking agents.
Main Results:
- Onset of neuromuscular blockade is generally faster in pediatric patients than adults.
- Rocuronium and rapacuronium demonstrate onset times comparable to succinylcholine.
- Recovery from mivacurium and rapacuronium is similar to succinylcholine, with potentially fewer adverse effects.
Conclusions:
- Newer agents like rocuronium and rapacuronium present viable alternatives to succinylcholine in pediatric anesthesia.
- The development of rapacuronium with rapid onset and duration may further reduce the reliance on succinylcholine.
Abstract:
Neuromuscular blocking agents are used commonly in paediatric anaesthesia, both to facilitate tracheal intubation and during surgery. Paediatric patients differ from adults in certain pharmacokinetic and pharmacodynamic characteristics. However, because maturational changes in certain of these characteristics counterbalance, dosing requirements do not differ markedly with age. In general, onset is more rapid in paediatric patients than in adults. Succinylcholine is still used commonly in children, despite restrictions by regulatory authorities, because of its rapid onset and offset. However, newer non-depolarizing neuromuscular blocking agents, particularly mivacurium, rocuronium and rapacuronium, offer many of the advantages of succinylcholine without its severe adverse effects: rocuronium and rapacuronium have an onset comparable with that of succinylcholine whereas the onset of mivacurium is slightly longer. In addition, recovery from an intubating dose of either mivacurium or rapacuronium is nearly comparable with that of succinylcholine. If rapacuronium i.m. proves to have a rapid onset without prolonged duration, the remaining value of succinylcholine will diminish.